Aspira Women's Health Inc., alongside its subsidiaries, specializes in the development and commercialization of diagnostic tools for gynecologic diseases across the United States. Their product portfolio includes tests such as OVA1, OVERA, and OVA1plus, designed to evaluate the risk of ovarian malignancy in women presenting with adnexal masses. Additionally, they provide ASPiRA GenetiX, a genetic screening option for assessing individual susceptibility to gynecologic cancers. The company operates Aspira Synergy, a cloud-based platform enabling decentralized access to protein biomarker and hereditary genetic testing. Furthermore, Aspira owns and manages ASPiRA LABS, a specialized laboratory dedicated to applying advanced biomarker technologies for the management of gynecologic cancers and related conditions. Its innovation pipeline features upcoming products like OVAWatch, EndoCheck, and OVAInherit. Aspira serves a diverse clientele, including individual physicians, physician office laboratories, and both national and regional laboratory networks. The company actively collaborates with several institutions, holding a research agreement with Baylor Genetics and another with Harvard Dana-Farber Cancer Institute, Brigham and Women's Hospital, and Medical University Lodz to explore microRNA technology for enhanced early ovarian cancer detection. A strategic alliance is also in place with Quest Diagnostics, Incorporated. Incorporated in 1993 and headquartered in Austin, Texas, the company adopted its current name, Aspira Women's Health Inc., in June 2020, having previously operated as Vermillion, Inc.